Literature DB >> 20944071

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Brian A Walker1, Christopher P Wardell, Laura Chiecchio, Emma M Smith, Kevin D Boyd, Antonino Neri, Faith E Davies, Fiona M Ross, Gareth J Morgan.   

Abstract

We used genome-wide methylation microarrays to analyze differences in CpG methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presentation myeloma, and plasma cell leukemia). We show that methylation patterns in these cell types are capable of distinguishing nonmalignant from malignant cells and the main reason for this difference is hypomethylation of the genome at the transition from MGUS to presentation myeloma. In addition, gene-specific hypermethylation was evident at the myeloma stage. Differential methylation was also evident at the transition from myeloma to plasma cell leukemia with remethylation of the genome, particularly of genes involved in cell-cell signaling and cell adhesion, which may contribute to independence from the bone marrow microenvironment. There was a high degree of methylation variability within presentation myeloma samples, which was associated with cytogenetic differences between samples. More specifically, we found methylation subgroups were defined by translocations and hyperdiploidy, with t(4;14) myeloma having the greatest impact on DNA methylation. Two groups of hyperdiploid samples were identified, on the basis of unsupervised clustering, which had an impact on overall survival. Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944071     DOI: 10.1182/blood-2010-04-279539

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  105 in total

Review 1.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

2.  DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.

Authors:  Jerome Moreaux; Angelique Bruyer; Jean-Luc Veyrune; Hartmut Goldschmidt; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

Review 3.  Genomics in multiple myeloma.

Authors:  Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

4.  NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Authors:  Sathisha Upparahalli Venkateshaiah; Sharmin Khan; Wen Ling; Rakesh Bam; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; Joshua Epstein; Shmuel Yaccoby
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

Review 5.  Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Authors:  Daphné Dupéré-Richer; Jonathan D Licht
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

Review 6.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 7.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 9.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

10.  TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Authors:  Stacy Grieve; Gabriel Wajnberg; Miranda Lees; Simi Chacko; Jackson Weir; Nicolas Crapoulet; Tony Reiman
Journal:  Blood Adv       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.